Story perspectives

Merck's Keytruda: $163B in Revenue, Access Limited by Pricing

4/15/2026

Summary

Story summary

Merck's Keytruda has generated over $163 billion since its launch, yet prices limit access.
An investigation by the International Consortium of Investigative Journalists (ICIJ) reveals Merck filed over 1,200 patents to extend exclusivity through 2042.
Critics say pricing prioritizes profit over patient access, and costs vary across countries, with some patients crowdfund or sue.
The investigation calls for urgent reforms in drug pricing and distribution.

1 of 1

Story summary

Merck's Keytruda has generated over $163 billion since its launch, yet prices limit access.
An investigation by the International Consortium of Investigative Journalists (ICIJ) reveals Merck filed over 1,200 patents to extend exclusivity through 2042.
Critics say pricing prioritizes profit over patient access, and costs vary across countries, with some patients crowdfund or sue.
The investigation calls for urgent reforms in drug pricing and distribution.